5^th April 2007, London ApaTech, a world leader in bone graft technology, announces the European launch of Actifuse^TM ABX Easyfill Putty, a revolutionary new approach to bone grafting and the latest entry in the Company’s product line.

Actifuse Advanced Bone matriX (ABX) provides surgeons with Actifuse granules as a mouldable, cohesive mass in an easy to use applicator. As a result, Actifuse ABX can be placed straight into the operative site. Actifuse ABX provides surgeons with the handling benefits associated with demineralised bone matrix putties but in a product that is 96% granules.

Commenting on the launch of Actifuse ABX, CEO Simon Cartmell said ease of use coupled with rapid bone formation means that surgeons need look no further than Actifuse ABX for the majority of their bone grafting procedures. Whilst convenient to use, DBMs have up to 40% carrier that has no useful biological function and needs to be removed prior to bone formation. Also they do not contain osteo-conductive scaffold to support bone growth. Actifuse ABX is 96% Actifuse granules but formulated in a way that provides excellent handling and placement characteristics.”

Mr. Lester Wilson of the Royal National Orthopaedic Hospital, Stanmore, commented “We have used DBMs for many years since they can improve the handling of other bone graft substitutes. Actifuse ABX is the next generation material, combining the biological benefits of Actifuse scaffold with the placement benefits and mouldability of a putty.  It also means we no longer have to worry about issues of disease transmission and poor bone quality due to the donor variability inherent in DBMs. This is a tremendous step forward in bone grafting technology.”

The unique silicate substituted calcium phosphate chemistry of Actifuse is a significant advance in synthetic bone graft technology and provides surgeons with a safe and effective alternative to both autograft and allograft. Actifuse enhances the formation of bone and improves the subsequent organisation and strength of the graft/host bone composite structure.  Unlike traditional calcium phosphate based products, Actifuse is steadily and predictably remodelled by the host biology over time, ensuring that sufficient conductive scaffold remains for the duration of new bone growth and its subsequent maturation.

Distinct from allograft and demineralised bone matrix sourced from cadaveric bone, Actifuse ABX Easyfill putty is synthetic and as a result, free of pathogens. This means that there is no risk of infection due to human or animal infective agent transmission from the graft material, and being synthetic, there have been no reports of adverse immunological reactions.

Contact:

Simon Cartmell, Chief Executive Officer +44 (0)20 8731 4640 or +44 (0)796 645 3133

About ApaTech

ApaTech Limited, based in London, England, is a world leader in bone graft technologies. Founded in 2001 and based on research and intellectual property from London and Cambridge Universities, ApaTech has introduced a novel silicate substituted calcium phosphate bone graft material, Actifuse^TM globally. The company believes that Actifuse is the first of a new class of synthetic bone graft material that combines osteoconductive and osteostimulatory activities.

Actifuse is available as a range of granule and microgranule formulations, including in an EasyPrep applicator and as an Advanced Bone matriX, Actifuse ABX Easyfill Putty.